Extracellular Fluid in Resistant Hypertension
The optimal treatment of drug resistant (defined as BP> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant...
Brief Summary
Official Title: “A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension”
The optimal treatment of drug resistant (defined as BP> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Detailed Clinical Trial Description
Following recruitment subjects will have ECV measured by 51Cr-EDTA determination of GFR, with Brochner-Mortensen correction applied. Subjects then receive the following drugs, in a randomised fashion, for a period of four weeks each, with BP & ECV measurement at end of each period: doxazosin GITS (Cardura XL) 4 mg b.d.; frusemide 40 mg b.d.; amiloride 5 mg b.d.; placebo.
Intervention(s) in this Clinical Trial
- Drug: Cardura XL 4 mg bd
- Drug: Amiloride 5 mg bd
- Drug: Furosemide 40 mg bd
Outcome Measures for this Clinical Trial
Primary Measures
- Change in ECV; change in BP
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- BP >140/85
- 3 antihypertensive drugs (ACE/ARB + calcium channel blocker + thiazide diuretic)
Exclusion Criteria:
- Pregnancy
- Breast Feeding
- Unstable heart failure
- Chronic Liver Disease
- Creatinine >120 mcmol/L
- Contraindication to (or intolerance of) drug used in study
- BP > 180/110
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 80 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: St George's, University of London Other
Overall Clinical Trial Officials and Contacts
Timothy WR Doulton, BSc MRCP Principal Investigator SGUL
Overall Contact: Timothy WR Doulton, BSc MRCP +44 208 725 3176 tdoulton@sgul.ac.uk
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00141596
Study ID Number: LREC 03.0001
ClinicalTrials.gov Identifier: NCT00141596
Health Authority: United Kingdom: Research Ethics Committee
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00141596
